FAQ: Scinai Immunotherapeutics Ltd. Receives Italian Clearance for Option to Acquire Pincell S.r.l.
Summary
What is the significance of Scinai Immunotherapeutics receiving Italian clearance?
The clearance under Italy’s Golden Power regulation allows Scinai to proceed with its option to acquire Pincell S.r.l., expanding its inflammation and immunology pipeline with Pincell’s lead asset, PC111, which targets severe skin disorders.
Who issued the regulatory clearance for Scinai Immunotherapeutics?
The approval was issued by Italy’s Coordination Group and Ministry of Health.
What is Pincell S.r.l.’s lead asset and its significance?
Pincell’s lead asset is PC111, a monoclonal antibody targeting the Fas/FasL pathway, which holds Orphan Drug Designation in Pemphigus and is being developed for severe skin disorders.
What are the final conditions for the acquisition of Pincell by Scinai?
The acquisition remains subject to final conditions, including a €12 million grant decision expected later this summer.
How does this acquisition fit into Scinai Immunotherapeutics’ business strategy?
The acquisition supports Scinai’s strategic move to expand its inflammation and immunology pipeline, complementing its in-house development of biological therapeutic products and its boutique CDMO services.
Where can I find more information about Scinai Immunotherapeutics?
More information is available on the company’s website at www.Scinai.com and the latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
What is the expected timeline for the final grant decision regarding the acquisition?
The €12 million grant decision is expected later this summer.
What are the two complementary business units of Scinai Immunotherapeutics?
Scinai has one business unit focused on in-house development of inflammation and immunology biological therapeutic products, and a second business unit that is a boutique CDMO providing biological drug development and related services to early stage biotech companies.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 110076